265 related articles for article (PubMed ID: 33819109)
21. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
Wu J
J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
[TBL] [Abstract][Full Text] [Related]
22. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
23. A comparative study to alternatives to the log-rank test.
Dormuth I; Liu T; Xu J; Pauly M; Ditzhaus M
Contemp Clin Trials; 2023 May; 128():107165. PubMed ID: 36972865
[TBL] [Abstract][Full Text] [Related]
24. Sequential tests for non-proportional hazards data.
Brückner M; Brannath W
Lifetime Data Anal; 2017 Jul; 23(3):339-352. PubMed ID: 26969674
[TBL] [Abstract][Full Text] [Related]
25. Investigating non-inferiority or equivalence in time-to-event data under non-proportional hazards.
Möllenhoff K; Tresch A
Lifetime Data Anal; 2023 Jul; 29(3):483-507. PubMed ID: 36708450
[TBL] [Abstract][Full Text] [Related]
26. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
Yu C; Huang X; Nian H; He P
Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
[TBL] [Abstract][Full Text] [Related]
27. Optimality of testing procedures for survival data in the nonproportional hazards setting.
Arfè A; Alexander B; Trippa L
Biometrics; 2021 Jun; 77(2):587-598. PubMed ID: 32535892
[TBL] [Abstract][Full Text] [Related]
28. Power and sample size calculation for log-rank test with a time lag in treatment effect.
Zhang D; Quan H
Stat Med; 2009 Feb; 28(5):864-79. PubMed ID: 19152230
[TBL] [Abstract][Full Text] [Related]
29. Robust group sequential designs for trials with survival endpoints and delayed response.
Ghosh P; Ristl R; König F; Posch M; Jennison C; Götte H; Schüler A; Mehta C
Biom J; 2022 Feb; 64(2):343-360. PubMed ID: 34935177
[TBL] [Abstract][Full Text] [Related]
30. Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
Demirhan H; Demirhan YP; Bacanli S
J Biopharm Stat; 2013 Mar; 23(2):447-60. PubMed ID: 23437950
[TBL] [Abstract][Full Text] [Related]
31. A win ratio approach for comparing crossing survival curves in clinical trials.
Zheng S; Wang D; Qiu J; Chen T; Gamalo M
J Biopharm Stat; 2023 Jul; 33(4):488-501. PubMed ID: 36749067
[TBL] [Abstract][Full Text] [Related]
32. Two-sample inference procedures under nonproportional hazards.
Tai YC; Wang W; Wells MT
Pharm Stat; 2023; 22(6):1016-1030. PubMed ID: 37429738
[TBL] [Abstract][Full Text] [Related]
33. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
34. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
35. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
[TBL] [Abstract][Full Text] [Related]
36. Non-proportional hazards in immuno-oncology: Is an old perspective needed?
Magirr D
Pharm Stat; 2021 May; 20(3):512-527. PubMed ID: 33350587
[TBL] [Abstract][Full Text] [Related]
37. On information fraction for Fleming-Harrington type weighted log-rank tests in a group-sequential clinical trial design.
Kundu MG; Sarkar J
Stat Med; 2021 May; 40(10):2321-2338. PubMed ID: 33624861
[TBL] [Abstract][Full Text] [Related]
38. Stochastic curtailment tests for phase II trial with time-to-event outcome using the concept of relative time in the case of non-proportional hazards.
Sharma P; Phadnis MA
J Biopharm Stat; 2024 Jul; 34(4):596-611. PubMed ID: 37574976
[TBL] [Abstract][Full Text] [Related]
39. Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week.
Gregson J; Sharples L; Stone GW; Burman CF; Öhrn F; Pocock S
J Am Coll Cardiol; 2019 Oct; 74(16):2102-2112. PubMed ID: 31623769
[TBL] [Abstract][Full Text] [Related]
40. Three-component cure rate model for nonproportional hazards alternative in the design of randomized clinical trials.
Kim HT; Gray R
Clin Trials; 2012 Apr; 9(2):155-63. PubMed ID: 22353928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
